Teladoc stock sinks on disappointing Q2 revenue and future guidance. Here’s why caution is warranted in buying the dip in TDOC shares today.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Moby summary of Teladoc Health, Inc.'s Q2 2026 earnings call
Teladoc Health (NYSE:TDOC) reported second-quarter results within its consolidated guidance range, supported by stronger-than-expected profitability in its Integrated Care segment, while lower cash-pay revenue at BetterHelp prompted the company to reduce its full-year revenue outlook. Consolidated
Teladoc (TDOC) delivered earnings and revenue surprises of +12.50% and -1.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Digital medical services platform Teladoc Health (NYSE:TDOC) will be announcing earnings results this Wednesday after the bell. Here’s what investors should know.
HCA (HCA) delivered earnings and revenue surprises of +0.26% and 0.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Teladoc Health (NYSE:TDOC) reported first-quarter 2026 results that Chief Executive Officer Chuck Divita said came in above the midpoint of the company’s guidance for both revenue and Adjusted EBITDA, driven by solid performance in Integrated Care and continued progress scaling BetterHelp’s insuranc
Moby summary of Teladoc Health, Inc.'s Q1 2026 earnings call
Teladoc Health Inc (TDOC) reports robust revenue growth and strategic advancements in AI and insurance, despite challenges in cash flow and business model shifts.